22.10: Disposal of haemopoietic progenitor cells Disposal of cellular therapy products shall include the following requirements shall meet the EBMT guideline requiments (Chapter D12: Dis…
22.5: Donor selection, consent and testing Establishments must have detailed policies and procedures for the testing and assessment of donors of stem cells. These must be in accordance w…
22.4: Adverse events and reactions 22.4.1: HTA Guide for the management of serious adverse events (SAEs) and reactions (SARs) All licensed establishments must have a system in…
22.3: Policy and procedure requirements and Safety 22.3.1: HTA licensing and requirements The procurement and testing of human tissues or cells in UK should only be carried ou…
22.2: Terminology This chapter aligns with the terminology described at FACT-JACIE International Standards for Haemopoietic Cellular Therapy, Product Collection, Processing,…
22.6: Collection, processing and storage Stem Cells and Therapeutic Cells should only be collected in a hospital facility or Blood Service apheresis unit with appropriate experience (see…
JPAC Position Statement on Zika - September 2023.pdf (118KB)
CN 34-2023 - France, Italy and Spain (WNV & Dengue) v1.pdf (2MB)
JPAC Validation of Dried Plasma.pdf (304KB)
CN 33-2023 - Coronavirus Infection v1.pdf (377KB)
UKBTS General Information 03 - Deviations from 4 C temp storage for red cells - June 2016.pdf (508KB)